Originally developed as a lipolytic / anti-obesity agent; later studied for cartilage repair via influence on chondrocyte proliferation.
Reference facts
- Also known as
- Anti-Obesity Drug 9604, hGH 177-191
- Category
- Healing & Tissue Repair
- Mechanism of action
- Originally developed as a lipolytic / anti-obesity agent; later studied for cartilage repair via influence on chondrocyte proliferation.
- Targets
- β3-adrenergic receptor (proposed), Chondrocyte signaling
- Indications under research or approved
- Failed Phase 2 obesity (2007); research in osteoarthritis
- Regulatory status (reference entry)
- Not FDA-approved (cosmetic GRAS in some jurisdictions)
- Half-life
- ~38 minutes
- Sequence
- YLRIVQCRSVEGSCGF
- Sequence notes
- 16-residue C-terminal fragment of human growth hormone (177-191) with an added N-terminal tyrosine; intramolecular disulfide between Cys7-Cys13.
- Molecular weight (Da)
- 1815
- Originator / sponsor
- Originally Metabolic Pharmaceuticals (Australia)
- First reported
- 2002
Primary References
Explore research articles about AOD-9604
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.